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OBJECTIVES: To examine the independent relationships
between ﬁbrin D-dimer, interleukin 6 (IL-6), C-reactive
protein (CRP), and ﬁbrinogen and incident mobility limita-
tion and mortality.
DESIGN: Prospective.
SETTING: General practice in 24 British towns.
PARTICIPANTS: Men aged 60 to 79 without prevalent
heart failure followed up for an average of 11.5 years
(N = 3,925).
MEASUREMENTS: All-cause mortality (n = 1,286) and
self-reported mobility disability obtained at examination in
1998 to 2000 and in a postal questionnaire 3 to 5 years
later in 2003.
RESULTS: High D-dimer (top vs lowest tertile: adjusted
odds ratio (aOR) = 1.46, 95% conﬁdence interval = 1.02–
2.05) and IL-6 (aOR = 1.43, 95% CI = 1.01–2.02) levels
(but not CRP or ﬁbrinogen) were associated with greater
incident mobility limitation after adjustment for confound-
ers and prevalent disease status. IL-6, CRP, ﬁbrinogen,
and D-dimer were signiﬁcantly associated with total mor-
tality after adjustment for confounders. Only D-dimer and
IL-6 predicted total mortality independent of each other
and the other biomarkers. The adjusted hazard ratio
(aHR) was 1.16 (95% CI = 1.10–1.22) for a standard
deviation increase in log D-dimer and 1.10 (95%
CI = 1.04–1.18) for a standard deviation increase in log
IL-6. D-dimer was independently related to vascular and
nonvascular mortality, and IL-6 was independently related
to vascular mortality. Risks of mobility limitation and
mortality were greatest in those with a combination of
high D-dimer and IL-6 levels.
CONCLUSION: D-dimer and IL-6 are associated with risk
of mobility limitation and mortality in older men without
heart failure. The ﬁndings suggest that coagulation leads to
functional decline and mortality s that inﬂammation does
not explain. J Am Geriatr Soc 62:2357–2362, 2014.
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A
ging is characterized by chronic low-grade inﬂamma-
tion that is involved in the pathophysiology and course
of many age-related disorders.
1 Proinﬂammatory cytokines
such as interleukin 6 (IL-6) play a central role in the hepatic
production of C-reactive protein (CRP), ﬁbrinogen, and
other acute-phase proteins involved in the inﬂammatory
process and may also play a role in the activation of coagu-
lation.
2 Fibrin D-dimer, a marker of on-going ﬁbrin
formation and degradation, is the most commonly used
clinical assay for the detection of activation of the coagula-
tion system.
3 D-dimer is also an acute-phase reactant whose
production stimulates high levels of cytokines such as IL-6
inﬂuence.
4 In turn, D-dimer and other ﬁbrin degradation
products may also inﬂuence inﬂammatory and acute-phase
responses by promoting neutrophil and monocyte activa-
tion, inducing the release of IL-6.
5
High circulating levels of markers of inﬂammation
and coagulation, most notably CRP, IL-6, and D-dimer
increase with advancing age
1,6 and have been associated
with functional decline, cardiovascular disease (CVD), and
total mortality.
7–22 Whether the association between CRP
and mobility limitation and mortality reﬂects upregulation
by IL-6 is not well established. Few studies have examined
to what extent the inﬂammatory and coagulation path-
ways are independently associated with mobility limitation
and mortality, although is has been suggested that coagula-
tion pathways have mechanisms independent of inﬂamma-
tion.
13 The association between IL-6, CRP, D-dimer, and
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mortality was therefore assessed in men aged 60 to 79,
and whether the association between D-dimer and incident
mobility limitation and mortality was attributable to IL-6
or CRP (or vice versa) was assessed.
METHODS AND PARTICIPANTS
The British Regional Heart Study is a prospective study of
CVD involving 7,735 men aged 40 to 59 selected from
one general practice in each of 24 British towns who were
screened between 1978 and 1980.
23 The population stud-
ied was socioeconomically representative of British men
but consisted almost entirely of white Europeans (>99%).
In 1998 to 2000, all surviving men, now aged 60 to 79,
were invited for a 20-year follow-up examination. The
men completed a questionnaire (Q20) that included ques-
tions on their medical history and lifestyle. They were
requested to fast for a minimum of 6 hours, during which
time they were instructed to drink only water and to
attend for measurement at a prespeciﬁed time between
8:00 a.m. and 6:00 p.m. All men were asked to provide a
blood sample. Four thousand two hundred ﬁfty-two men
(77% of survivors) attended an examination. Follow-up
data using self-reported questionnaires (Q03) were col-
lected in 2003. Four thousand forty men had at least one
of the four markers (D-dimer, IL-6, CRP, or ﬁbrinogen)
and biochemistry measured. Men with a diagnosis of heart
failure (n = 115), who have high disability rates and
exceptionally high mortality, were excluded. Heart failure
is associated with abnormal hemostasis and inﬂamma-
tion,
24 and individuals with heart failure are likely to be
taking anticoagulants and other treatments that might
have biased the associations between inﬂammation, coagu-
lation, mobility, and mortality. After these exclusions,
3,925 men were available for analysis.
Cardiovascular Risk Factor Measurements at the
20-Year Examination (1998–2000)
Details of measurements and classiﬁcation methods for
smoking status, physical activity, body mass index, social
class, blood pressure, blood lipids, and glucose have been
described.
25–27 CVD included recall of a doctor’s diagnosis
of myocardial infarction, angina pectoris, stroke, deep vein
thrombosis (DVT), or peripheral vascular disease. Plasma
D-dimer levels were measured using an enzyme-linked
immunosorbent assay (ELISA; Biopool AB, Umeå, Swe-
den). C-reactive protein was assayed using ultrasensitive
nephelometry (Dade Behring, Milton Keynes, UK). IL-6
was assayed using a high-sensitivity ELISA (R & D Sys-
tems, Oxford, UK). Fibrinogen was assayed using an auto-
mated Clauss assay in a coagulometer (MDA-180,
Organon Teknika, Cambridge, UK).
Mobility Limitation
At the 20-year examination (1998–2000) and on the fol-
low-up questionnaire in 2003, the men were asked
whether they currently had difﬁculty (i) going up or down
stairs, (ii) bending down or straightening up, (iii) keeping
their balance, or (iv) walking one-quarter of a mile on the
level on their own as a result of a long-term health prob-
lem. Mobility limitation was deﬁned as reporting difﬁculty
in (i) and (iv).
27 Analysis of incident mobility limitation
(Table 1) was restricted to the 2,731 men who responded
to the 2003 follow-up questionnaire and were free of
mobility limitation at the 20-year examination (Figure 1).
Follow-Up
All men have been followed up from initial examination
(1978–1980) to December 2010 for all-cause mortality and
cardiovascular morbidity,
28 and follow-up has been achieved
for 99% of the cohort. In the present analyses, all mortality
follow-up was based on follow-up from rescreening in 1998
to 2000 (aged 60–79) and a mean follow-up of 11.5 years
(range 10.5–12.5 years). Information on death was collected
through the National Health Service registers. Cardiovascu-
lar deaths include all those with International Classiﬁcation
ofDiseases, NinthRevision,codes 401to 459.
Statistical Methods
Analyses are based on the division of the distribution of CRP,
IL-6, ﬁbrinogen, and D-dimer into equal thirds in all 3,925
men. Cox proportional hazards models were used to assess
the multivariate-adjusted relative risk. In the adjustment,
smoking (never, long-term ex-smoker (>15 years), recent ex-
smoker, current smoker), social class (seven groups), physical
activity (four groups), alcohol intake (ﬁve groups), preexist-
ing diabetes mellitus (yes/no), CVD (yes/no), respiratory
medication (yes/no), self-rated health (poor/fair), and use of
antihypertensive drugs (yes/no) were ﬁtted as categorical
variables. Body mass index, systolic blood pressure, and
high-density lipoprotein cholesterol were ﬁtted as continuous
variables. Logistic regression was used to determine adjusted
oddsratiosofincident mobilitylimitation (Table 1).
RESULTS
During a mean follow-up of 11.5 years, there were 1,286
deaths from all causes (497 CVD, 786 non-CVD, 3
unknown)in the3,925 menwith nodiagnosed heart failure.
C-reactive protein was signiﬁcantly correlated with
IL-6 (correlation coefﬁcient (r) = 0.57), ﬁbrinogen
(r = 0.48), and D-dimer (r = 0.33). Table 1 shows the
association between the four markers and adjusted odds of
incident mobility limitation (n = 288). D-dimer and IL-6,
but not CRP or ﬁbrinogen, were signiﬁcantly associated
with greater odds of incident mobility limitation after
adjustment for lifestyle characteristics and disease status
(Model 1). The association between D-dimer and incident
mobility limitation remained signiﬁcant after adjustment
for IL-6 and was strengthened after exclusion of men with
prevalent CVD or those who reported a diagnosis of CVD
at follow-up (top vs bottom tertile: adjusted odds
ratio = 1.63, 95% CI = 1.03–2.58). Adjustment for
D-dimer slightly attenuated the association between IL-6
and mobility limitation and the association was no longer
signiﬁcant. The combined effect of D-dimer and IL-6 was
examined. Those with high IL-6 and D-dimer had much
higher odds of incident mobility limitation than having
just one high marker (Table 1).
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CVD, and non-CVD mortality for a 1-standard deviation
increment in CRP, IL-6, and D-dimer, with stepwise
adjustment for the biomarkers. CRP, IL-6, and D-dimer
were signiﬁcantly associated with total, CVD, and
non-CVD mortality after adjustment for lifestyle charac-
teristics and disease status. These associations remained
signiﬁcant even after exclusion of men with prevalent
CVD or cancer (n = 1,246) (data not shown). The associ-
ation between CRP and CVD mortality was attenuated
when adjustment was made for IL-6. IL-6 and D-dimer
levels were associated with total, CVD, and non-CVD
mortality independent of CRP. D-dimer emerged as the
strongest predictor of total, CVD, and non-CVD mortal-
ity when all three markers (IL-6, CRP, D-dimer) were
included in the model. Fibrinogen was signiﬁcantly
associated with total, CVD, and non-CVD mortality after
adjustment for lifestyle characteristics and disease status,
but these associations were attenuated after adjustment
for CRP (data not shown).
The joint effect of D-dimer and IL-6 on total mortality
was also examined. High D-dimer and IL-6 levels con-
ferred by far the highest risk of mortality. Compared to
those with low D-dimer and low IL-6, the adjusted relative
risk of mortality for having high IL-6 alone was 1.31
(95% CI = 1.02–1.68), high D-dimer alone was 1.36
(95% CI = 1.07–1.73), and having high IL-6 and D-dimer
was 2.07 (95% CI = 1.63–2.64).
DISCUSSION
This large population study of British men aged 60 to 79
conﬁrmed the ﬁndings of previous prospective studies that
ﬁbrin D-dimer and IL-6 are associated with incident
mobility limitation
11–16 and total mortality
16–22 indepen-
dent of lifestyle characteristics and established cardiovascu-
lar risk factors. These ﬁndings add to the limited literature
on the prospective associations between D-dimer and total
and nonvascular mortality and extend those of previous
studies on D-dimer, CRP, IL-6, and ﬁbrinogen and mobil-
Table 1. Associations Between Tertiles of D-Dimer, C-Reactive Protein (CRP), Interleukin (IL)-6, and Fibrinogen
and Incident Mobility Limitation (n = 288 cases) and Adjusted Odds Ratio of Incident Mobility Limitation in
2,731 Men Who Reported No Prevalent Mobility Limitation and No Prevalent Heart Failure
Tertile N
Incident
Mobility, %
Age Adjusted Model 1 Model 2
Odds Ratio of Incident Mobility Limitation
(95% Conﬁdence Interval)
D-dimer, ng/mL
Low (<58) 1,028 7.1 1.00 1.00 1.00
Middle (58–103) 947 10.8 1.35 (0.98–1.86) 1.25 (0.88–1.74) 1.23 (0.88–1.73)
Upper (>104) 749 15.1 1.76 (1.27–2.45) 1.46 (1.03–2.06) 1.42 (1.00–2.01)
Test for trend P = .006 P = .03 P = .05
CRP, mg/L
Low (<1.03) 1,019 6.5 1.00 1.00
Middle (1.03–2.57) 926 11.1 1.82 (1.32–2.51) 1.31 (0.94–1.85)
Upper (>2.58) 763 13.6 2.06 (1.48–2.85) 1.23 (0.86–1.77)
Test for trend P < .001 P = .31
IL-6, pg/mL
Low (<1.77) 1,027 6.7 1.00 1.00 1.00
Middle (1.78–2.91) 919 10.8 1.45 (1.05–2.01) 1.21 (0.87–1.72) 1.19 (0.84–1.67)
Upper (>2.92) 759 15.5 2.20 (1.60–3.02) 1.43 (1.01–2.02) 1.35 (0.95–1.92)
Test for trend P < .001 P = .04 P = .10
Fibrinogen (g/L)
Low (<2.93) 989 7.7 1.00 1.00
Middle (2.93–3.43) 941 11.1 1.34 (0.98–1.84) 1.21 (0.87–1.68)
Upper (>3.44) 794 13.6 1.63 (1.19–2.24) 1.17 (0.83–1.64)
Test for trend P = .002 P = .91
Composite index: IL6 and D-dimer
0 (both low) 491 5.5 1.00 1.00
1 (middle tertile of IL6 or D-dimer) 649 8.2 1.38 (0.86–2.24) 1.19 (0.73–1.96)
2 (middle tertile of both) 347 12.91 1.52 (0.90–2.59) 1.26 (0.72–2.18)
3 (high IL-6 only) 469 12.6 2.10 (1.30–3.39) 1.32 (0.80–2.20)
4 (high D-dimer only) 455 11.7 1.69 (1.03–2.79) 1.33 (0.79–2.23)
4 (both markers high) 287 20.6 3.20 (1.95–5.22) 1.88 (1.11–3.19)
Test for trend P < .001 P = .01
Missing data: D-dimer, n = 7; CRP, n = 23; IL-6, n = 26; ﬁbrinogen, n = 7.
Model 1 adjusted for age, smoking, physical activity, alcohol intake, social class, body mass index, diabetes mellitus, history of cardiovascular disease or
cancer, respiratory medication, self-rated health, use of antihypertensive drugs, and systolic blood pressure.
Model 2: For IL-6, adjustments were made for factors in Model 1 and for D-dimer. For D-dimer, adjustments were made for factors in Model 1 and for
IL-6.
Test for trend across the groups.
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ers in the same study and assessing their independent rela-
tionships.
D-Dimer Levels, Inﬂammation, and Mobility Limitation
IL-6, but not CRP or ﬁbrinogen, was associated with
mobility limitation independent of lifestyle characteristics
and disease status. Weaker associations between CRP
and mobility limitation have also been reported in other
studies.
12,15 Although a number of studies have reported
an association between D-dimer, inﬂammation (in partic-
ular IL-6 levels), and incident mobility limitation in the
general population,
12,13,16 few have assessed the indepen-
dence and the interaction of these factors. Chronic
inﬂammation has been proposed as a biological mecha-
nism underlying age-associated functional decline. D-
dimer has been shown to stimulate production of IL-6
and other inﬂammatory mediators that have been
directly associated with loss of muscle mass and
strength, which leads to mobility limitation, but the
association between D-dimer and mobility limitation was
independent of IL-6 in multivariate analysis, although
activation of coagulation (D-dimer) and inﬂammation
(IL-6) was associated with a much greater risk of mobil-
ity limitation than high D-dimer levels alone. This ﬁnd-
ing suggests independent effects of coagulation on
mobility function and of an interaction between coagula-
tion and the inﬂammation system on mobility function.
Although the mechanism by which D-dimer may directly
inﬂuence mobility limitation is not clear, D-dimer may
have a direct inﬂuence on mobility limitation by modu-
lating the function of immunocytes to produce cytokines
and other mediators with roles in cell migration, vascu-
lar remodeling, and endothelial cell activation.
13 D-dimer
may also be an important component of age-related
Excluded: 
Death before the study  (n=2,040)and 
official emigration (n=34)
Excluded: 
Those excluded by GP, those living overseas 
and those who self withdrew (n=114)
1978-1980
Original BRHS cohort
N=7,735
1998-2000
4,272 men attended 
examination
Total invited to screen at 1998-2000 study 
N=5,447
Excluded 232 men with no 
measurments on D-dimer, CRP, 
IL-6, and fibrinogen
Excluded 115 men with heart 
failure
3,258 men responded to 
follow-up questionnaire 
in 2003
Study sample N=3,925
Excluded 527 men with 
mobility limitation at 
1998-2000 examination
2,731 men free of mobility 
limitation in 1998-2000 included 
in analysis
December 2010
1,286 deaths after mean 
11.5 years follow-up
288 men reported mobility 
limitation at 2003
Figure 1. Flowchart displaying the study cohort and participants included in the analysis of mobility limitation and all-cause
mortality. BRHS = British Regional Heart Study; GP = general practitioner; CRP = c-reactive protein; IL-6 = interleukin 6.
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quent mortality,
29 although this remains speculative.
Inﬂammation, D-Dimer Levels, and Mortality
Inﬂammatory markers, including CRP, IL-6, and ﬁbrino-
gen, have been associated with mortality in numerous
population studies.
7,8,17–22 Only IL-6 emerged as an inde-
pendent predictor of mortality when other inﬂammatory
markers were taken into account. The current ﬁndings that
the association between CRP and CVD mortality was attenu-
ated after adjustment for IL-6 support the suggestion that
IL-6 may play an important role in mediating the associa-
tions between downstream inﬂammatory markers such as
CRP and CVD.
30 Fibrinogen is an acute-phase reactant pro-
tein that rises with tissue inﬂammation and is a vital part of
the common pathway of the coagulation process, although
ﬁbrinogen was not related to vascular or nonvascular mortal-
ity after adjustment for CRP, as seen in other studies.
20
Fewer studies have examined the association between D-
dimer and total and nonvascular mortality in the general
population. The current study found a strong association
between D-dimer and total, CVD, and non-CVD mortality
that was independent of inﬂammation, consistent with other
studies.
17–19
STRENGTHS AND LIMITATIONS
Strengths and limitations of this study require consider-
ation. The study population was socially representative of
the United Kingdom, and follow-up rates in the British
Regional Heart Study are exceptionally high. This study is
based on a cohort of older (60–79) men, and the results
need further conﬁrmation in similar study populations and
in middle-aged populations and women. Because mobility
outcome is based on survivors who responded to the fol-
low-up questionnaire 4 years later, survival bias may have
weakened the true association between coagulation,
inﬂammation, and mobility limitation.
CONCLUSION
Inﬂammation and coagulation are associated with mobility
limitation and mortality. The ﬁndings suggest that acti-
vated coagulation leads to functional decline and death
that inﬂammation does not explain. If so, future studies of
new oral anticoagulants (which reduce coagulation activa-
tion and D-dimer) in older persons (e.g., with atrial ﬁbril-
lation) might reduce the risk of mobility limitation and
vascular morbidity and mortality.
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Table 2. Mortality Associated with a 1-Standard Deviation (SD) Increase in Log C-Reactive Protein (CRP), Inter-
leukin (IL)-6, and D-Dimer
Mortality
Model 1 Model 2 Model 3
Adjusted Hazard Ratio (95% Conﬁdence Interval)
Total
Log CRP 1.17 (1.09–1.25) <.001 1.09 (1.02–1.17) .01 1.07 (1.00–1.14) .08
Log IL-6 1.18 (1.12–1.25) <.001 1.14 (1.06–1.21) <.001 1.10 (1.04–1.18) .006
Log D-dimer 1.20 (1.15–1.26) <.001 1.17 (1.11–1.23) <.001 1.16 (1.10–1.22) <.001
CVD
Log CRP 1.21 (1.11–1.32) <.001 1.09 (0.98–1.22) .11 1.06 (0.95–1.18) .36
Log IL-6 1.25 (1.14–1.37) <.001 1.19 (1.07–1.32) .003 1.14 (1.02–1.26) .04
Log D-dimer 1.30 (1.19–1.41) <.001 1.27 (1.17–1.37) <.001 1.24 (1.15–1.35) <.001
Non CVD
Log CRP 1.14 (1.07–1.22) <.001 1.09 (1.001–1.19) .04 1.07 (0.98–1.17) .12
Log IL-6 1.15 (1.08–1.23) <.001 1.13 (1.01–1.26) .03 1.08 (0.99–1.19) 0.07
Log D-dimer 1.14 (1.07–1.22) <.001 1.12 (1.03–1.21) .004 1.11 (1.04–1.18) .008
1-SD increase in log IL-6 = 0.67, log CRP = 1.11, log D-dimer = 0.84, ﬁbrinogen = 0.73.
Model 1 adjusted for age, smoking, physical activity, alcohol intake, social class, body mass index, diabetes mellitus, history of cardiovascular disease
(CVD) or cancer, self- rated health, use of antihypertensive drugs, systolic blood pressure, high-density lipoprotein cholesterol, and forced expiratory
volume in 1 second.
Model 2: Adjusted for factors in Model 1and CRP. For CRP, adjustment was made for IL-6.
Model 3: Adjusted for factors in Model 1 and all three biomarkers (CRP, IL-6, D-dimer).
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